Source:http://linkedlifedata.com/resource/pubmed/id/20122674
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
2010-2-3
|
| pubmed:abstractText |
Nanocarriers can selectively target cancer sites and carry payloads, thereby improving diagnostic and therapeutic effectiveness and reducing toxicity. The objective of this study was to investigate the therapeutic efficacy of a new co-delivery radiochemotherapeutics of (188)Re-N,N-bis (2-mercaptoethyl)-N',N'-diethylethylenediamine (BMEDA)-labeled pegylated liposomal doxorubicin (DXR) ((188)Re-DXR-liposome) in a C26 murine colon carcinoma solid tumor model. To evaluate the targeting and localization of (188)Re-DXR-liposome in C26 murine tumor-bearing mice, biodistribution, microSPECT/CT imaging and pharmacokinetic studies were performed. The antitumor effect of (188)Re-DXR-liposome was assessed by tumor growth inhibition, survival ratio and histopathological hematoxylin-eosin staining. The tumor target and localization of the nanoliposome delivery radiochemotherapeutics of (188)Re-DXR-liposome were demonstrated in the biodistribution, pharmacokinetics and in vivo nuclear imaging studies. In the study on therapeutic efficacy, the tumor-bearing mice treated with bimodality radiochemotherapeutics of (188)Re-DXR-liposome showed better mean tumor growth inhibition rate (MGI) and longer median survival time (MGI=0.048; 74 days) than those treated with radiotherapeutics of (188)Re-liposome (MGI=0.134; 60 days) and chemotherapeutics of Lipo-Dox (MGI=0.413; 38 days). The synergistic tumor regression effect was observed with the combination index (CI) exceeding 1 (CI=1.145) for co-delivery radiochemotherapeutics of (188)Re-DXR-liposome. Two (25%) of the mice treated with radiochemotherapeutics were completely cured after 120 days. The therapeutic efficacy of radiotherapeutics of (188)Re-liposome and the synergistic effect of the combination radiochemotherapeutics of (188)Re-DXR-liposome have been demonstrated in a C26 murine solid tumor animal model, which pointed to the potential benefit and promise of the co-delivery of nanoliposome radiochemotherapeutics for adjuvant cancer treatment on oncology applications.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jan
|
| pubmed:issn |
1872-9614
|
| pubmed:author | |
| pubmed:copyrightInfo |
Copyright 2010 Elsevier Inc. All rights reserved.
|
| pubmed:issnType |
Electronic
|
| pubmed:volume |
37
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
95-104
|
| pubmed:meshHeading |
pubmed-meshheading:20122674-Animals,
pubmed-meshheading:20122674-Autoradiography,
pubmed-meshheading:20122674-Cell Line, Tumor,
pubmed-meshheading:20122674-Colonic Neoplasms,
pubmed-meshheading:20122674-Combined Modality Therapy,
pubmed-meshheading:20122674-Disease Models, Animal,
pubmed-meshheading:20122674-Doxorubicin,
pubmed-meshheading:20122674-Drug Stability,
pubmed-meshheading:20122674-Drug Therapy,
pubmed-meshheading:20122674-Injections, Intravenous,
pubmed-meshheading:20122674-Male,
pubmed-meshheading:20122674-Maximum Tolerated Dose,
pubmed-meshheading:20122674-Mice,
pubmed-meshheading:20122674-Radioisotopes,
pubmed-meshheading:20122674-Radiotherapy,
pubmed-meshheading:20122674-Rhenium,
pubmed-meshheading:20122674-Survival Analysis,
pubmed-meshheading:20122674-Tissue Distribution,
pubmed-meshheading:20122674-Tomography, Emission-Computed, Single-Photon,
pubmed-meshheading:20122674-Treatment Outcome,
pubmed-meshheading:20122674-Tumor Burden,
pubmed-meshheading:20122674-X-Ray Microtomography
|
| pubmed:year |
2010
|
| pubmed:articleTitle |
Therapeutic efficacy and microSPECT/CT imaging of 188Re-DXR-liposome in a C26 murine colon carcinoma solid tumor model.
|
| pubmed:affiliation |
Institute of Nuclear Energy Research, Taoyuan, Taiwan, ROC.
|
| pubmed:publicationType |
Journal Article
|